全主动脉弓置换术后托伐普坦给药的安全性与有效性
本研究纳入2016年8月至12月因胸主动脉瘤行全主动脉弓置换术的11例患者,在常规利尿剂呋塞米20 mg和螺内酯25 mg基础上口服托伐普坦7.5 mg,结果显示给药后1至3天尿量增加,体重逐步稳定下降至出院,给药期间未发现肝肾功能障碍,结论认为托伐普坦联合常规利尿剂对全主动脉弓置换术后液体管理安全有效。
要点
- 全主动脉弓置换术后在呋塞米20 mg和螺内酯25 mg基础上加用托伐普坦7.5 mg口服。
- 托伐普坦给药后1至3天尿量增加,体重逐步稳定下降至出院。
- 给药期间未发现肝肾功能障碍。
核心结论
- 托伐普坦联合常规利尿剂对使用体外循环、选择性脑灌注和深低温停循环的全主动脉弓置换术后液体管理安全有效。
研究设计与样本
- 本研究于2016年8月至2016年12月纳入11例因胸主动脉瘤行全主动脉弓置换术的患者。
- 在常规利尿剂呋塞米20 mg和螺内酯25 mg基础上,口服托伐普坦7.5 mg。
主要发现
- 托伐普坦给药后1至3天尿量增加。
- 体重逐步稳定下降直至出院。
- 托伐普坦给药期间未发现肾功能或肝功能障碍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative fluid overload in cardiovascular surgery is associated with increased mortality and morbidity. Recently, tolvaptan (TLV), a selective vasopressin V2 antagonist, has been used for perioperative fluid management. This study aimed to validate the safety and effectiveness of TLV administration after total arch replacement (TAR) using selective cerebral perfusion. METHODS: From August 2016 to December 2016, 11 patients who had undergone TAR for thoracic aortic aneurysm were included in this study. In addition to the conventional diuretics furosemide (20 mg) and spironolactone (25 mg), TLV (7.5 mg) was administered orally. RESULTS: TLV increased urine output 1-3 days after administration. Body weight was gradually and steadily reduced until discharge. Neither renal nor liver dysfunction was recognized during the TLV administration. CONCLUSION: The concomitant use of TLV and conventional diuretics is safe and effective for fluid management after TAR using cardiopulmonary bypass, selective cerebral perfusion, and hypothermic circulatory arrest.
引用
- Iida Y, Yoshitake A, Shimizu H, et al. Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement. Ann Vasc Surg. 2018. PMID: 30342208. doi:10.1016/j.avsg.2018.08.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。